Recent Updates
Recently added Catalysts

SER-252

Phase 1

PARKINSON DISEASE (Disorder) | Small molecule | Neurology |AgeX Therapeutics, Inc.|Last Updated: Mar 2, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical trial landscape

SER-252 · 1 trial · 2 indications

Phase 1 1
NCT07422675SAD Study in Patients With Parkinson's Disease and Motor FluctuationsPARKINSON DISEASE (Disorder)
RECRUITING40 Analytics
PHASE1RECRUITING
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
PARKINSON DISEASE (Disorder)
NCT0742267540
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
SER-252 (PEOZ-apomorphine)DRUGSER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product.
enFuseDEVICEThe enFuse® device is a sterile, non-pyrogenic, user-filled, single-use, fixed-dose subcutaneous dose delivery system.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT07422675studyFirstPostDate: changed